Clinical trial · Observational
PACE4 in Thyroid Cancer
Evaluation of PACE4 Isoforms as Biomarkers in Thyroid Cancer
NCT03160482CI-TRIAL-00035105completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The investigation of thyroid nodules is limited by the fact that up to 49% of the fine needle aspirations (FNA) performed are of "indeterminate cytological signification". Moreover, no fully reliable molecular marker for thyroid cancer have been described. The goal of this project is to study the expression of a specific kind of protein convertase in benign and in malignant thyroid nodules to determine its potential as a biomarker.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Thyroid Nodule | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Immunohistochemistry | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (9)
- label
- Papillary carcinoma, classical variant
- interventionNames
- Diagnostic Test: Immunohistochemistry
- label
- Follicular carcinoma
- interventionNames
- Diagnostic Test: Immunohistochemistry
- label
- Colloid nodule
- interventionNames
- Diagnostic Test: Immunohistochemistry
- label
- Hyperplastic nodule
- interventionNames
- Diagnostic Test: Immunohistochemistry
- label
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 100 Years
Show eligibility criteria text
Inclusion Criteria: * Men of women, aged 18-100 y.-o. * History of subtotal or total thyroidectomy at the "Centre intégré universitaire de santé et de services sociaux de l'Estrie - Centre hospitalier universitaire de Sherbrooke" (CIUSSS de l'Estrie - CHUS) between January 2010 and May 2016. Exclusion Criteria: * Refusal to participate to the study. * Unavailability of the formalin-fixed, paraffin-embedded tissues. * Uncertain pathological diagnosis.
References
Publications (1)
- DERIVEDFradet L, Temmar R, Couture F, Belzile M, Fortier PH, Day R. Evaluation of PACE4 isoforms as biomarkers in thyroid cancer. J Otolaryngol Head Neck Surg. 2018 Oct 19;47(1):63. doi: 10.1186/s40463-018-0311-x. PMID 30340539